Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at Bentley University published a paper investigating the involvement of government…
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means fewer generic entrants and less opportunities for consumers to enjoy…
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today under a Creative Commons…
This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal of Pharmaceutical Research and Development. 2020; 8(4): 194-212 under an…
When drug patents expire, billions of dollars in revenues can disappear overnight as competitors enter the market. Accordingly, many investors focus on drug patents when evaluating drug companies. But, there…
Just because a drug has received FDA approval does not mean that it is available in the marketplace. But, why would a company go through all the trouble and expense…
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th Portfolio Management & Pipeline Optimization for Generics from September 30th…
The USPTO Office of the Chief Economist has releases a comprehensive set of patent litigation data files for public use. The Patent Litigation Dataset has been updated as of December…
The FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations, is the definitive source to link drugs with the patents that protect them. Over the years we’ve had…
This article was originally published by Syed Sauban Ghani in Eclética Química under a Creative Commons license. ABSTRACT As scientific community worldwide is publishing a huge number of research articles…
